As a national high-tech enterprise, Suzhou Senbomed Medical Technology Co., Ltd. focuses on the drug delivery device field, with continuous innovation and high-caliber R&D as core competitiveness, providing professional solutions for global pharmaceutical companies.
Specializing in inhalation drug delivery devices and injection pens, the company has a top-tier R&D team with European backgrounds, boasting successful development experience in 13 types of oral/nasal inhalation devices. Its R&D scope covers soft mist, dry powder, capsule-based systems, disposable auto-injectors and adjustable injection pens, widely applied in asthma treatment, anti-diabetic, weight-loss and immunotherapy fields, with several product lines achieving full equivalence to original branded devices.
Adhering to Scientific Injection Molding, Senbomed has obtained 36 domestic and 7 international patents, covering core technologies like injection pen anti-collision design, dosage adjustment feedback, audio prompts and injection speed reduction. The team excels in patent circumvention and technology commercialization; some products have completed U.S. DMF filing to support global market registration.
Strictly complying with ISO 13485 and pharmacopoeia requirements of China, the U.S. and the EU, Senbomed participates in drafting the 2025 Edition national pharmacopoeia standard for Inhalation Preparation Packaging Systems. With academician academic resources and supercomputing support, it has established an in vitro bioequivalence evaluation laboratory, offering one-stop services from product design to assembly production. It has established strategic partnerships with leading listed companies, empowering the pharmaceutical industry's high-quality development.
